HVTN 111

A phase 1 clinical trial to evaluate the safety and immunogenicity of HIV clade C DNA and of MF59-adjuvanted clade C Env protein, in healthy, HIV-uninfected adult participants,

Enrollment Opened


-To evaluate safety and tolerability of clade C DNA and bivalent gp120 protein and MF59 adjuvant in each vaccine regimen.

-To evaluate  immune responses of clade C DNA and bivalent gp120 protein and MF59 adjuvant in each vaccine regimen.

Trial design

Multicenter, randomized, controlled, double-blind trial conducted in six sites in Southern African countries.




You can reach us at:

NIMR - Mbeya Medical Research Center
P.O Box 2410
Hospital Hill rd, Mbeya Tanzania

Tel +255 25 250 3364
Fax +255 25 250 3134

Working hours:
Mon - Fri
08:00 - 17:00 EAT (GMT + 3)

Or send us an email at This email address is being protected from spambots. You need JavaScript enabled to view it.

Our Twitter Feed

NIMRMbeya RT @KatharinaKranz4: @NIMRMbeya has recruited 500 household contact for the @EraseTb study. Another milestone reached. Congratulations 🎉🍾🎊…
NIMRMbeya Enjoy reading 📃 https://t.co/NWYLWX83Sb
NIMRMbeya RT @Oweksha: It is possible to remove TB diagnosis delay once patients reach the health system at any level -- when facilities are equiped…
NIMRMbeya Dr. Nyanda appreciated the participation of all 16 RECs in 🇹🇿 that participated in the bioethics ToT and commended… https://t.co/MtXpPHVJ2x
NIMRMbeya Dr. Mayassa Ally, DG of Zanzibar Health Research Institute welcomed researchers from Tanzania mainland to also cont… https://t.co/26mKoLyG8T
© 2017 NIMR - Mbeya Medical Research Center